Valneva, the new fully integrated European biotech company created in 2013 through the merger between Vivalis and Intercell, has announced the launch of a fully underwritten €40 million capital increase with preferential subscription rights.

Hogan Lovells, who has advised Vivalis in relation to its merger with Intercell, also advised Valneva and the Banks on this capital increase. The team in charge of this deal was made up of Jean-Marc Franceschi, Paris Corporate partner, assisted by Thomas Saint-Loubert-Bié, as well as for the tax aspects, Virginie Aïdan, and for the international aspects, John Basnage, London Corporate partner, assisted by Jaime Huertas.

http://www.hoganlovells.com/newsmedia/newspubs/detail.aspx?news=2686